Article
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Oct 2024
Leighl Natasha B, Akamatsu Hiroaki, Lim Sun Min, Cheng Ying, Minchom Anna R, Marmarelis Melina E, Sanborn Rachel E, Chih-Hsin Yang James, Liu Baogang, John Thomas, Massutí Bartomeu, Spira Alexander I, Lee Se-Hoon, Wang Jialei, Li Juan, Liu Caigang, Novello Silvia, Kondo Masashi, Tamiya Motohiro, Korbenfeld Ernesto, Moskovitz Mor, Han Ji-Youn, Alexander Mariam, Joshi Rohit, Felip Enriqueta, Voon Pei Jye, Danchaivijitr Pongwut, Hsu Ping-Chih, Silva Melo Cruz Felipe José, Wehler Thomas, Greillier Laurent, Teixeira Encarnação, Nguyen Danny, Sabari Joshua K, Qin Angel, Kowalski Dariusz, Şendur Mehmet Ali Nahit, Xie John, Ghosh Debopriya, Alhadab Ali, Haddish-Berhane Nahor, Clemens Pamela L, Lorenzini Patricia, Verheijen Remy B, Gamil Mohamed, Bauml Joshua M, Baig Mahadi, Passaro Antonio
Abstract excerpt
PURPOSE: Phase III studies of intravenous amivantamab demonstrated efficacy across epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC). A subcutaneous formulation could improve tolerability and reduce administration time while maintaining efficacy. PATIENTS AND METHODS: Patients with EGFR-mutated advanced NSCLC who progressed after osimertinib and platinum-based...
Read the complete abstract on PubMed